In 1997, Eli Lilly US and Eli Lilly Canada (collectively, “Eli Lilly”) brought an action against Apotex Inc., (“Apotex”) claiming damages for patent infringement under s.55(1) of the Patent Act for its bulk import of cefaclor for use in Apo-cefaclor, which it sold in Canada. In 2014, the Federal Court awarded damages for lost profits, and an award of compound interest. Apotex appealed both.